The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index
Table 3
Overall survival and time to first therapy data of the MDACC PI, the CLL-IPI, and the Barcelona-Brno biomarkers only prognostic model risk groups.
MDACC PI
Group
Median OS (95% CI)
5-year OS
10-year OS
HR (95% CI)
Low risk
160
238.5 (146–330.0)
98.4
91.6
1 (ref)
Intermediate risk
302
142 (132–151.9)
79.6
61.6
4.8 (2.6–9.1)
<0.0001
High risk
21
63.5 (52.6–74.4)
51.1
15.3
5.3 (0–9.2)
<0.0001
Group
Median TTFT (95% CI)
5-year TTFT
10-year TTFT
HR (95% CI)
Low risk
160
133.0 (110.8–155.3)
20.3
47.5
1 (ref)
Intermediate risk
302
81 (46.6–115.4)
44.9
55.7
2.2 (1.5–3.1)
<0.0001
High risk
21
2.3 (0.3–4.4)
93.7
93.7
4.4 (3.2–6)
<0.0001
CLL-IPI
Group
Median OS (95% CI)
5-year OS
10-year OS
HR (95% CI)
Low risk
126
238.5 (147–330)
93.6
89.6
1
Intermediate risk
79
144.8 (127.8–161.8)
87.6
74.5%
3.2 (1.5–6.7)
<0.0001
High risk
49
73.7 (56.6–90.7)
67.8
26.8
2.2 (2.1–4.8)
<0.0001
Very high risk
7
31.8 (21.2–42.4)
28.6
NE
4.4 (3.2–6)
<0.0001
Group
Median TTFT (95% CI)
5-year TTFT
10-year TTFT
HR (95% CI)
Low risk
126
Not reached
15.8
29.4
1 (ref)
Intermediate risk
79
52.9 (34.5–71.3)
55
79.1
4.4 (2.7–7.2)
<0.0001
High risk
46
7.6 (5–10)
93.4
93.4
3.7 (2.8–4.9)
<0.0001
Very high risk
7
9.6 (0–21)
NE
NE
2.2 (1.6–3.2)
<0.0001
Barcelona-Brno PI
Group
Median OS (95% CI)
5-year OS
10-year OS
HR (95% CI)
Low risk
145
238.5 (146.8–330)
90.7
86
1 (ref)
Intermediate risk
91
131.9 (95–167.9)
81.4
61.1
4.34 (2.85–6.63)
<0.0001
High risk
22
Not reached
66.2
53
9.37 (5.12–17.14)
<0.0001
Group
Median TTFT (95% CI)
5-year TTFT
10-year TTFT
HR (95% CI)
Low risk
142
182.2 (83.9–280.4)
19.9
35.8
1 (ref)
Intermediate risk
91
31.5 (14.4–48.5)
64.7
82.4
2.95 (1.57–5.52)
<0.0001
High risk
21
9.8 (2.4–17.2)
91.6
91.6
4.24 (1.67–10.97)
<0.0001
NE: not evaluable. NE: last control in month 94. NE: last control in month 45. MDACC: MD Anderson Cancer Center. CLL-IPI: chronic lymphocytic leukemia international prognostic index.
